Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome-Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant… Or, Rather, Temporary Dual Antiplatelet Therapy?

Indeed, the RE-DUAL PCI study actually showed a trend towards a higher rate of myocardial infarction and stent thrombosis in the subgroup of patients treated with dabigatran 110 mg twice daily + a single antiplatelet drug with a P2Y 12 inhibitor, as compared to a “classical” TAT strategy including warfarin, aspirin, and a P2Y 12 inhibitor [ 2 ] (this was not apparent, however, in the dabigatran 150 mg twice daily + single antiplatelet drug) [ 2 ].

also in 53,322 other papers

Moreover, DAPT yielded a highly significant reduction in the risk of intracranial hemorrhage, although this finding might have been amplified by the use of warfarin instead of NOAC in the TAT group [ 17 , 18 ].

also in 132,142 other papers